Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg
dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with
varying degrees of renal impairment